Mobile

A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast canc...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002819-40

A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives for this study are as follows: • To explore the efficacy of T-DM1 compared with the combination of trastuzumab and docetaxel in patients with HER2-positive, unresectable, locally advanced breat cancer and/or metastatic breat cancer who have not received prior chemotherapy for metastatic disease, as measured by PFS based on investigator assessments • To evaluate the safety of T-DM1 compared with the combination of trastuzumab and docetaxel in this population

Critère d'inclusion

  • HER2 positive metastatic breast cancer

Liens